© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Americas Committee for Treatment and Research in Multiple Sclerosis
Multiple Sclerosis Care Professionals Satisfied With Clinical Video Telemedicine Visits
March 06, 2021
Researchers found that the percentage of telemedicine visits increased from 15% to 72.8% during the COVID-19 pandemic.
Electronic Pill Bottle Improves DMT Adherence, Subcutaneous Cladribine Personalized Dosing Well-Tolerated, MS Fatigue Unchanged Long-Term
March 06, 2021
Neurology News Network for the week ending March 6, 2021.
ACTRIMS 2021 Post-Conference Expert Perspective: Jeffrey Cohen, MD
March 05, 2021
The president of the Americas Committee for Treatment and Research in MS discusses his takeaways from this year’s virtual forum.
Understanding the Momentum in the Autoimmune Encephalitis Research Community
March 05, 2021
The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.
African American Patients with MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients
March 04, 2021
Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.
How COViMS Registry Is Clarifying MS COVID-19 Risks: Amber Salter, MPH, PhD
March 04, 2021
The assistant professor of biostatistics at Washington University in St. Louis discussed what role the COViMS registry can play for the MS community at this stage in the pandemic.
Human Oligodendrocyte Differences Due to Environmental Signals Rather Than Lineage
March 04, 2021
Researchers used single-cell RNA sequencing on adult, pediatric, and infant surgical tissues to study oligodendrocyte types in order to better understand multiple sclerosis.
High Rates of MS Relapse after TNFα Inhibitor Discontinuation: Spencer Hutto, MD
March 03, 2021
The fellow of autoimmune neurology at Massachusetts General Hospital discusses the ongoing question about whether the demyelination is an unmasking of disease or consequence of the treatment.
Predicting MS Disability With IL-1 Receptor Antagonist Levels: Stephanie Blandford, MSc
March 03, 2021
The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed her team’s investigations into the use of IL-1RA as a biomarker for MS disability.
NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs
March 03, 2021
The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.